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The profile and trajectory of cognitive impairment in mitochondrial disease
are poorly defined. This systematic review sought to evaluate the current liter-
ature on cognition in mitochondrial disease, and to determine future research
directions. A systematic review was conducted, employing PubMed, Medline,
Psycinfo, Embase and Web of Science, and 360-degree citation methods. Eng-
lish language papers on adult patients were included. The literature search
yielded 2421 articles, of which 167 met inclusion criteria. Case reports and
reviews of medical reports of patients yielded broad diagnoses of dementia,
cognitive impairment and cognitive decline. In contrast, systematic investiga-
tions of cognitive functioning using detailed cognitive batteries identified focal
cognitive rather than global deficits. Results were variable, but included visu-
ospatial functioning, memory, attention, processing speed and executive func-
tions. Conclusions from studies have been hampered by small sample sizes,
variation in genotype and the breadth and depth of assessments undertaken.
Comprehensive cognitive research with concurrent functional neuroimaging
and physical correlates of mitochondrial disease in larger samples of well-char-
acterized patients may discern the aetiology and progression of cognitive defi-
cits. These data provide insights into the pattern and trajectory of cognitive
impairments, which are invaluable for clinical monitoring, health planning
and clinical trial readiness.
Introduction
Mitochondrial diseases are a common group of
genetic neuromuscular disorders characterized by
genotypic and phenotypic heterogeneity, with a preva-
lence similar to that of many other genetically deter-
mined neurodegenerative diseases [1]. Although there
is significant clinical variability, neurological impair-
ment remains a hallmark of mitochondrial disease and
cognitive impairment is one of the least understood
aspects.
A review of clinical manifestations by El-Hattab and
colleagues [2] identified initial symptoms of developmen-
tal delay in <10% of patients and impaired mentation in
10–24% of patients referred to as having mitochondrial
encephalopathy, lactic acidosis and stroke-like episodes
(MELAS). Overall, 50–74% featured learning disability
or memory impairment and ≥90% experienced demen-
tia. Prevalence rates of cognitive difficulties have ranged
from 0 to 90%, depending on genotype and stage of dis-
ease [3–10]. These findings would indicate variable cog-
nitive outcomes for patients with mitochondrial disease.
Nevertheless, to date, our knowledge of intellectual abil-
ity in patients with mitochondrial disease and how this
may change with disease progression remains scarce.
The purposes of this systematic review were twofold: (i)
to investigate current literature on cognition in mitochon-
drial disease and (ii) to determine how the field must
advance to improve our knowledge of cognition in this
group.
Methods
Throughout this systematic review, we have adhered
to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines for
conducting systematic reviews [11].
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Search strategy
We independently searched five databases (PubMed,
Medline, Psycinfo, Embase and Web of Science) for
articles published up to and including 10 June 2019.
Search terms related to mitochondrial disease and to
cognitive functioning were chosen, based on the indi-
vidual thesaurus used in each database (full search
terms are provided in Tables S1–S5). Papers were fur-
ther identified through manual search strategies and
using 360-degree citation methods to ensure that the
breadth of the literature was comprehensively screened
(Fig. 1).
Review criteria
Inclusion criteria were English language, human stud-
ies of adult patients (≥16 years) with primary mito-
chondrial disease. Child studies were excluded unless
part of a family study. No robust animal models yet
exist for the common forms of mitochondrial disease
associated with cognitive impairment; thus, animal
research was excluded. Papers were considered if they
referred to cognitive functioning in the title or
abstract, or to discussion of clinical findings1. Exclu-
sion criteria were: other diseases/disorders commonly
associated with mitochondrial dysfunction (e.g.
Creutzfeldt–Jakob disease, Friedreich’s ataxia, Parkin-
son’s disease, Huntington’s disease), diseases of mem-
ory without mitochondrial disease (e.g. Alzheimer’s
disease, dementia), psychiatric problems without con-
current cognitive difficulties, unpublished data, confer-
ence presentations and abstracts where the full paper
was not published.
Data synthesis
Due to substantial methodological and clinical hetero-
geneity in systematic research studies identified by this
literature search (Table 1), we used a narrative approach
to synthesize the findings of the included studies, as
meta-analysis was deemed inappropriate [12].
Results
The literature search yielded 2421 articles, of which 168
met inclusion criteria. Articles were subdivided into case
literature (75% of published articles), reviews of the
medical literature (18%) and larger scale, systematic
investigations of cognition in mitochondrial disease
(7%; Fig. 1), categorized by mutation/phenotype.
Case literature
Many case reports have been published that give a
clinical profile of the patient(s) in question, including
a statement about cognition (Table 2), without refer-
ence to the neuropsychological assessments and/or
results obtained (see Table S6 for broader impair-
ments associated with cognitive difficulty and the ref-
erence list for both tables). Cognition was reported in
114 patients; 34% showed cognitive impairment, 24%
cognitive decline and 15% dementia. Cognitive
domains with high reports of impairment were mem-
ory (32%) and language (20%). However, to highlight
variability in reporting, only 2% identified dementia
and memory difficulties, 14% cognitive impairment
and memory difficulties, and 7% cognitive decline and
memory difficulties (which could constitute a diagnosis
of dementia, depending on the extent of impairment).
Comprehensive assessment of 14 patients with
MELAS revealed higher VIQ than PIQ, and intellectual
decline and dementia [24,25], as well as visuospatial dif-
ficulties [25,26], attention difficulties, verbal fluency,
set-shifting ability, planning and problem solving (sug-
gestive of executive dysfunction) [26,27], auditory agno-
sia (inability to process environmental sounds and
speech, in the absence of aphasia) [28–32] and under-
standing of sentences [26]. Magnetic resonance imaging
(MRI) of the brain generally revealed generalized atro-
phy [24–26,28] although electroencephalographic
results from one study were suggestive of focal lesions
[27]. Cognitive decline was commonly reported in
patients with point mutations [33–35]. Wide-ranging
difficulties were described, with all reports identifying
deficits in visuospatial functioning, memory and atten-
tion [33–37], but with variation in impairment in lan-
guage [33–35], processing speed [36,37], verbal fluency,
planning, and initiative and set-shifting (areas of
1Definitions of cognitive terms are as follows.Cognitive impairment:
difficulties in one or more domain of cognitive functioning, e.g.
knowledge, attention, memory or reasoning.Developmental delay:
delays in reaching developmental milestones compared with expected
levels for a child’s age.Intellectual decline/cognitive decline: decline in
cognitive abilities from previous levels.Dementia: decline in memory
or other thinking skills severe enough to reduce a person’s ability to
perform everyday activities.Full-scale IQ (FSIQ): general cognitive
abilities.Performance IQ (PIQ): non-verbal reasoning skills.Verbal
IQ (VIQ): verbal knowledge and reasoning skills.Memory: ability to
learn, remember and recall verbal information, e.g. remembering a
shopping list or a conversation with a friend, family member or
healthcare professional.Processing speed: how quickly a person can
take information in and use it.Executive function: higher order con-
trol processes that guide behaviour, help you to plan what to do,
monitor whether a plan is working, change plans if the first is not
working or stop yourself from doing something that you should
not.Visuospatial/visuoconstruction: use of visual information to
understand and interact with the environment, e.g. finding your way
around a car park or putting together flat-pack furniture.
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executive functioning) [35–37]. Relative strengths varied
across patients, with some showing better verbal [37]
and some showing better visual [33,34] abilities.
Reviews of the medical literature
A number of studies have reviewed different domains
of cognitive functioning in patients with mitochondrial
disease, often reporting variable frequencies of indi-
viduals with dementia, cognitive impairment and cog-
nitive decline (Table 3).
Kartsounis and colleagues [38] reviewed the medical
records of 72 patients with undefined mitochondrial
disease from 1969 to 1989. General or focal cognitive
deficits were observed in 61% of 36 patients who
underwent neuropsychological assessment. Moderate
to severe general intellectual decline was detected in
36%, defined by a discrepancy between estimated
optimal intelligence quotient (IQ) and performance on
general intelligence tests of ≥15 IQ points (15–30,
moderate; 30+, severe). A total of 16 patients demon-
strated memory deficits, 15 demonstrated perception
deficits and 12 demonstrated language deficits. Only
28% displayed normal higher cerebral functioning.
However, patients were assessed as part of clinical
care and it is not known what the cognitive ability of
untested individuals was, or whether they might have
exhibited subtle cognitive deficits that were unlikely to
be detected by initial clinical impression. This study
provided neither phenotype/genotype reflecting the
pre-genetic era, with only four reporting genotype
(Table 3) [39–42].
Figure 1 Process implemented to identify papers for this systematic review. [Colour figure can be viewed at wileyonlinelibrary.com]
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Larger-scale, systematic investigations of cognition
A total of 12 studies conducted systematic investiga-
tions of cognition in mitochondrial disease (Table 1).
Three studies investigated cognition in patients with
m.3243A>G. At initial assessment, Majamaa-Voltti
et al. [13] identified 16 patients as cognitively impaired
(50%). In the whole sample, executive dysfunction was
commonly observed, with 14 patients (14/32) failing to
complete the task. Cognitive progression was rare,
although data were not provided to corroborate this.
Kaufmann et al. [14] demonstrated that their fully
symptomatic patient group (n = 31) not only per-
formed worse than the asymptomatic/partially symp-
tomatic group but also showed progressively worse
cognition over time, whereas the asymptomatic/par-
tially symptomatic group remained stable. However,
specific assessments and results of cognitive domains
were not reported. Furthermore, high dropout rates
were evident between years 1 and 4, limiting the gen-
eralizability of results over time.
Kraya et al. [15] found that patients performed sig-
nificantly worse than controls on measures of visuo-
construction, Trail-Making Test (TMT) visual and
divided attention, set-switching/inhibition and verbal
fluency, but not on other measures of executive func-
tion, working/visual memory. Higher lesion load cor-
related with worse attention, visuoconstruction, list-
learning ability and verbal fluency. Increasing symp-
tom severity (measured by Newcastle Mitochondrial
Disease Adult Scale [43] correlated with worsening
attention, planning, verbal fluency and list learning.
One study investigating cognition in patients in
association with maternally-inherited diabetes and
deafness (MIDD) (m.3243A>G:9, m.14709T>G:2) [16]
found executive functioning and visual memory defi-
cits. The authors suggested that visual memory
impairment may be caused by executive dysfunction,
particularly as verbal memory was intact using a task
that minimized executive function load. Although cog-
nitive deficits were found in patients with MIDD, no
cognitive deficit was severe enough to fit dementia
Table 3 Prevalence of cognitive difficulties reported by review articlesa
Author Phenotype n Cognitive difficulties
Goto et al. MELAS 40 65% showed cognitive impairment
Hirano et al. MELAS 69 Dementia reported in 90% of cases Learning disability in 60% of cases
Damian et al. MELAS 21 Dementia/cognitive impairment in 5/21 cases
Chinnery et al. MELAS 111 27% of cases presented with dementia
Majamaa et al. MELAS 11 4/11 patients showed cognitive decline
Suzuki et al. m.3243A>G 113 7.1% showed cognitive impairment3.6% presented with dementia
Murakami et al. m.3243A>G 14 Current cognitive decline in 6/8 patients with prior diagnosis of
diabetes (75%) and 0/6 without prior diagnosis of diabetes
Chae et al. MELAS 18 Learning disability reported in 50% of cases
Sproule & Kaufmann MELAS 45 Memory problems reported in 71% of cases
Lorenzoni et al. MELAS 10 Developmental delay reported in 1/10
patientsDementia present in 5/10 patients
Ma et al. MELAS 47 33/47 probands (70.2%) showed cognitive impairment
Hammans et al. MERRF 18 Dementia in 22% of cases
Ozawa et al. MERRF 10 Cognitive deterioration in 50% of cases
Chinnery et al. MERRF 55 25% of cases presented with dementia
Sinha et al. MERRF 10 Cognitive decline in 7/10 patients
Lorenzoni et al. MERRF 6 6/6 had normal early development. 2/6 presented with of dementia
Mancuso et al. MERRF 34 2/34 presented with cognitive involvement (6%)
Pavlakis et al. MELAS/MERRF/KSS 97 9/11 MELAS, 11/16 MERRF, 34/70 KSS presented with dementia
Khambatta et al. KSS 35 11/35 presented with cognitive decline
Wray et al. KSS 8 4/8 presented with cognitive impairment
Van Goethem et al. Multiple deletions 8 Unspecified number with mild cognitive impairment
Winterthun et al. Multiple deletions 6 5/6 patients exhibited cognitive dysfunction
Hakonen et al. Multiple deletions 6 Mild to moderate cognitive impairment in 74% of cases
Horvath et al. Multiple deletions 19 Early-onset dementia in 11% of cases
Tzoulis et al. Multiple deletions 26 Suspected mild cognitive impairment in 8 patients, confirmed mild
cognitive impairment in 4 patients
Wong et al. Multiple deletions 61 Developmental delay or dementia reported in 66% of patients
Van Hove et al. Multiple deletions 56 Memory loss reported in 5% of patients
Na€ımi et al. Multiple deletions and depletions 15 1/15 presented cognitive impairment
Jaksch et al. Multiple point mutations 16 8/16 patients from 7 families presented with cognitive impairment
aReferences available in Appendix S1. KSS, Kearns-Sayre syndrome; MELAS, mitochondrial encephalopathy, lactic acidosis and stroke-like
episodes; MERFF, myoclonic epilepsy with ragged red fibers.
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criteria, as demonstrated by Mini-Mental State Exam-
ination scores within the normal range. When com-
pared with type 1 diabetics, patients with MIDD
showed worse attention, working memory and
abstract reasoning.
Two studies explored cognition in patients with large-
scale single mitochondrial DNA deletions. Turconi
et al. [7] found no impairment in FSIQ; however, PIQ
was lower than VIQ. Specific deficits were also found in
short-term memory and visuospatial abilities. Bosbach
et al. [17] observed no general intellectual decline or
dementia compared with controls (Table 1). However,
specific deficits were found in executive function, atten-
tion and visual construction. Examination of quality of
life demonstrated differences from the norm on a
number of measures; however, subjective wellbeing and
limitations in social activities did not differ significantly.
Only one study has investigated cognition in
patients with POLG-related mitochondrial disease
(N:8; mitochondrial spinocerebellar ataxia and epi-
lepsy phenotype). Gramstad et al. [18] found a mean
FSIQ of 77.4 (moderate impairment) and all patients
showed significantly better VIQ than PIQ. This led
the authors to suggest reduced cognitive functioning,
although five patients scored within the normal range.
Retesting one patient 3 years later showed declines in
FSIQ, VIQ and PIQ. A trend of lower IQ with
increasing age at assessment and duration of epilepsy
was noted, suggesting a profile of progressive cogni-
tive decline. Unfortunately, no statistical analyses
were reported to corroborate these claims.
Five systematic investigations of cognition have
included patients with variable genotypes. The assess-
ments of Lang et al. [19] showed that patients with KSS
performed best and those with MELAS performed
worst (PEO, 8; MELAS, 4; KSS, 3). Four out of 15
patients performed within the normal range (KSS, 2;
PEO, 2) and seven patients were impaired on more than
half of all subtests (PEO, 3; MELAS, 4). Patients
showed the highest number of deficits on TMT, suggest-
ing difficulties in tasks tapping executive functions,
although patient scores may have been affected on the
TMT by ophthalmoplegia or motor speed difficulties
(not considered by the authors). Over half of all patients
demonstrated memory impairment. Five patients
(MELAS, 3; PEO, 2) were diagnosed with dementia.
Although patients with MELAS were more severely
affected than patients with kearns-sayre syndrome KSS
or progressive external ophthalmoplegia PEO, there
appeared to be no readily identifiable pattern of deficits.
Montirosso et al. [20] demonstrated performance
and reaction time for patients (Table 1) and controls
on both tasks. However, electroencephalographic
activity showed a delayed N2 component, reflecting
early slowing of information processing, and reduced
P3 amplitude, highlighting dysfunction in post-percep-
tual resetting and updating of information. These
results indicated processing-speed problems at a neu-
ronal level, in the absence of cognitive impairment.
Kaufmann et al. [21] completed comprehensive neu-
ropsychological testing on 91 individuals from
34 m.3243A>G families and 15 individuals from two
m.8344A>G families. They identified progressively
worse neuropsychological performance in asymp-
tomatic, oligosymptomatic and symptomatic groups,
which correlated with estimates of brain ventricular
lactate. Cerebral lactate correlated not only with glo-
bal cognitive functioning, but also with tests specifi-
cally measuring frontal brain regions, which are rarely
affected by stroke-like episodes. Furthermore,
m.3243A>G probands showed lower neuropsychologi-
cal test scores than m.8344A>G probands, suggesting
genotypic variance in cognitive profiling. Although
this study assessed a large group of individuals, infor-
mation about the specific neuropsychological tests and
their results was limited.
Inczedy-Farkas et al. [22] found average FSIQ within
normal limits, and lower PIQ than VIQ scores. Pro-
nounced PIQ deficits were observed in processing speed
and visuospatial functioning. Despite average FSIQ
scores, the authors reported a general pattern of moder-
ate to severe cognitive impairment. Memory perfor-
mance was variable, with recall being differentially
more impaired than encoding/learning and retroactive
(but not proactive) interference. Although data from 13
control participants were collected, parametric statisti-
cal comparisons were not made with patients due to
genetic heterogeneity. Comparisons of effect sizes were
used, however, criteria of magnitude were not defined.
Our group [23] showed that patients had mild to mod-
erate pre-morbid cognitive impairment, but substantial
impairment in FSIQ, as well as distinct domains of ver-
bal comprehension, perceptual reasoning, working
memory, processing speed and memory. It was not clear
whether the executive dysfunction reported in this sam-
ple was caused by frontal difficulties, or simply slower
decision-making. These results were corroborated by
significant differences from controls, except for memory,
where performance was similar. This suggests that, in
this sample, memory was intact when pre-morbid cogni-
tion was controlled for. Cognitive decline appeared slow
and was unlikely in the short-term when other disease-
specific factors remained stable.
Discussion
This is the first review to report a systematic search of
the literature describing mitochondrial disease and
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cognition. Small sample sizes, genotypic variability and
the breadth and depth of assessments undertaken intro-
duced significant heterogeneity across studies precluding
a meta-analysis, as any interpretation would not be
meaningful and could introduce significant bias. As
such, our results provide a narrative synthesis of the lit-
erature.
Examination of the case literature commonly revealed
dementia, cognitive impairment and cognitive decline,
as well as other memory problems in patients with mito-
chondrial disease. Difficulties with language and atten-
tion were frequently reported, as well as personality and
mood disorders, whereas executive dysfunction was
rarely reported, although this was identified more fre-
quently with detailed assessment. Reviews of medical
reports provided broad diagnoses of impairment, and
dementia, learning disability, cognitive impairment and
cognitive decline were reported as common. It is difficult
to know whether the identified impairments represent
the common difficulties experienced by patients with
mitochondrial disease, or a more extreme end of func-
tioning of severely affected individuals who have war-
ranted clinical evaluation and intervention.
Systematic studies that have reported the results of
neuropsychological testing are much less indicative of
general cognitive impairment and dementia than is sug-
gested by the findings of case reports and review articles.
These results instead provide strong support for a profile
of focal cognitive deficits, rather than global difficulties,
in areas such as visuospatial functioning, memory,
attention, processing speed and executive functions. In
terms of clinical care, detailed descriptions of focal cog-
nitive difficulties are much more beneficial, as this infor-
mation can feed into the development of management
strategies. Further difficulties arise with understanding
the cognitive challenges faced by patients with mito-
chondrial disease as a group because the literature does
not currently apply a uniform classification system for
the severity of cognitive deficit. There has also been sub-
stantial variability in the range of cognitive assessments
used across systematic research studies identified by this
review and little discussion about suitability of mea-
sures. Consensus on this matter is challenging due to the
clinical heterogeneity found within this group of dis-
eases; however, consideration must be given to the phys-
ical limitations of the sample in question and how these
might affect performance. As an example, performance
on standard versions of the TMT [44] might be affected
by ocular movements across the test page, ataxia, mus-
cular weakness and fatigue.
Although the evidence is not strong enough to sub-
stantiate distinct genotype-specific cognitive profiles,
research considering genotypic variation in cognitive
functioning has postulated differences [19,21]. However,
with the exception of Kaufmann and colleagues [21],
most systematic investigations have remained small, and
clinical profiles and/or genetic mutations have varied
considerably, limiting the ability to generalize these find-
ings to the wider population of patients with mitochon-
drial disease. Currently, understanding about the
aetiology and progression of cognitive dysfunction is
limited. Virgilio and colleagues [45] found significantly
higher mutation load in patients with a severe clinical
phenotype than mild/moderate and asymptomatic phe-
notypes, but they did not explore the link with cognitive
functioning. More recently, our group [23] showed that
disease severity (measured by Newcastle Mitochondrial
Disease Adult Scale and urinary heteroplasmy), rather
than genotype, is a stronger predictor of cognitive abili-
ties. Research has also shown links between severity of
other symptoms related to mitochondrial disease (e.g.
cerebral lactate, nuclear factors) and general cognitive
performance [21,46], but specific cognitive domains have
not been robustly investigated. As highlighted in
Table 1, neuroimaging findings (where available) vary
greatly across studies. The current literature does not
clarify whether focal cognitive deficits and general cogni-
tive impairment/dementia are part of a continuum of
symptoms varying in severity, and how these relate to
focal lesions and generalized atrophy in patients, nor
how underlying mutation load accounts for these
changes. Unfortunately, neuroimaging data are too
scarce at present to determine the association between
cognitive difficulties and imaging results. Another
important consideration when interpreting cognitive
dysfunction is additional disease factors that may exac-
erbate cognitive performance on any given day (e.g. fati-
gue, mental health difficulties). Unfortunately, no
systematic research to date has addressed this.
Information about prognosis is also currently limited,
as most research investigating disease-specific factors
related to cognitive impairment has taken measure-
ments at a single time point. Samples in longitudinal
studies, to date, remain small and require validation.
Kaufmann et al. [14] found worse initial performance
and greater progression of general cognitive difficulties
over a 4-year period in fully symptomatic vs. asymp-
tomatic/partially symptomatic (relatives) patients with
m.3243A>G mutations. Conversely, our group showed
no change over 18 months when other disease-specific
factors remained stable, although decline between pre-
morbid and current cognition over the longer term was
predicted by disease severity. Samples in longitudinal
research remain small, and greater follow-up duration is
required to validate results. This is essential for under-
standing disease progression and trajectories of change,
in order to apply this to clinical monitoring and subse-
quent health planning.
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Conclusions
From this systematic review, patients with mitochon-
drial disease face high rates of cognitive difficulties, in
areas including (but not limited to) visuospatial func-
tioning, memory, attention, processing speed and
executive functions. However, there is a great deal of
variation in the specific deficits reported, and the pat-
tern and progression are not fully understood. In
order to advance this field, larger samples of well-
characterized patients should be assessed using com-
prehensive, systematic measures tapping different
domains of cognitive functioning, including real-time
functional imaging during assessments.
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